Farmacovigilanza

amifampridine phosphate

Mon, 18 Oct 2021 13:42:12 -0400
For the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults.

Lingua Italiano

Pharmacologic Interventions for the Treatment of Opioid-Induced Hyperhidrosis

Mon, 18 Oct 2021 10:04:29 -0400

Lingua Italiano

tafasitamab

Fri, 15 Oct 2021 12:02:19 -0400

Le tafasitamab est indiqué en combinaison avec le lénalidomide dans le traitement du lymphome diffus à grandes cellules B (LDGCB) en rechute ou réfractaire non spécifié chez l'adulte qui n'est pas admissible à une greffe autologue de cellules souches.

Lingua Italiano

Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Chlorhexidine Oral Care in Critically Ill Adults

Thu, 14 Oct 2021 11:22:14 -0400

Lingua Italiano

Rotational Thromboelastometry in Adult Patients Presenting with Trauma

Thu, 14 Oct 2021 11:22:10 -0400

Lingua Italiano

Digital Pathology Using Primary Case Sign-out

Thu, 14 Oct 2021 11:22:08 -0400

Lingua Italiano

Lupin Pharmaceuticals, Inc. Issues Voluntarily Nationwide Recall of All Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets Due to Potential Presence of N-nitrosoirbesartan Impurity

Baltimore, Maryland, October 14, 2021: Lupin Pharmaceuticals Inc. is voluntarily recalling the below-mentioned batches of Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets to the consumer level. As part of Lupin’s ongoing assessment, analysis revealed that certain tested API batches

Lingua Italiano